NCCN Pharmacy Updates: Navigating the Challenging Treatment Landscape for HIV-Associated, Non-AIDS Defining Cancers
The NCCN Guidelines for Cancer in People with HIV maintain that, although modifications to highly-active antiretroviral therapy (HAART) may be needed, HIV therapy should be continued during cancer therapy, and both an HIV pharmacist and an oncology pharmacist should be consulted regarding drug interactions between these two therapeutic classes. Until recently, patients with HIV have been excluded from clinical trials resulting in a paucity of information regarding potential drug-drug and drug-disease interactions. The incidence of non-AIDS-defining cancers (NADCs) in HIV-positive patients is increasing, and pharmacists should understand and apply pharmacokinetic parameters in order to identify potential interactions and recommend change in therapy or modifications in dosing and/or administration to aid medical oncologists in choosing the right drug at the right dose given at the right time.
Target Audience
This program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician associates/assistants, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Compare and contrast the risks of development of non-AIDS defining malignancies in people living with HIV versus HIV-negative patients.
- Summarize the principles of HIV management while undergoing cancer therapy.
- Outline principles of supportive care for preventing infectious complications in patients receiving highly active antiretroviral therapy (HAART) and cancer treatment.
- Discuss the pharmacokinetics affecting metabolism and primary routes of elimination of antiretroviral therapies and potential for clinically significant interactions with anticancer agents in patients with HIV and NADCs.
Alisha Soares, PharmD, BCOP
UC San Diego Health
Shannon Balcombe, PharmD, BCPS, AAHIVP
UC San Diego Health
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Shannon Balcombe, PharmD, BCPS, AAHIVP
Alisha Soares, PharmD, BCOP
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses.
Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-087-L02-P
Physician Associates/Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 ANCC Pharmacology Contact Hours
- 1.00 Participation
Price
This webinar was presented live one time only on Tuesday, August 6, 2024, from 12:00 – 1:00 PM EDT (UTC -4).
The recorded activity is available here.
NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.
To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing